These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38662527)

  • 1. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma.
    McLinden GP; Avery AC; Gardner HL; Hughes K; Rodday AM; Liang K; London CA
    J Vet Intern Med; 2024; 38(3):1666-1674. PubMed ID: 38662527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
    Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
    Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
    Mizuno T; Kato Y; Kaneko MK; Sakai Y; Shiga T; Kato M; Tsukui T; Takemoto H; Tokimasa A; Baba K; Nemoto Y; Sakai O; Igase M
    Sci Rep; 2020 Jul; 10(1):11476. PubMed ID: 32651429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of CD20
    Ewing TS; Pieper JB; Stern AW
    Vet Dermatol; 2019 Feb; 30(1):51-e14. PubMed ID: 30474245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
    Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
    Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
    Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
    Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.
    Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W
    Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
    Maloney DG; Liles TM; Czerwinski DK; Waldichuk C; Rosenberg J; Grillo-Lopez A; Levy R
    Blood; 1994 Oct; 84(8):2457-66. PubMed ID: 7522629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
    Sakai O; Ogino S; Tsukui T; Igase M; Mizuno T
    J Vet Med Sci; 2021 Oct; 83(10):1495-1499. PubMed ID: 34408098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.
    Sonoki T; Li Y; Miyanishi S; Nakamine H; Hanaoka N; Matsuoka H; Mori I; Nakakuma H
    Int J Hematol; 2009 Apr; 89(3):400-402. PubMed ID: 19330555
    [No Abstract]   [Full Text] [Related]  

  • 17. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
    Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
    Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
    Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.